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Introduction
Psoriasis is a T-cell-mediated inflammatory disease that
affects the skin and occurs in one to two per cent of the
general population. In 1964, an association between
inflammatory arthritis (IA) and psoriasis was formally
recognised, although it was probably first described by
Alibert in 1818 [1]. The existence of psoriatic arthritis
(PsA) as a distinct clinical entity, however, remains a topic
of debate, with some clinicians arguing that it simply rep-
resents the coincidental occurrence of psoriasis and
inflammatory arthritides such as rheumatoid arthritis (RA)
or ankylosing spondylitis [2]. A review of the investigation
of PsA genetic susceptibility factors is, therefore, both
controversial and complex.
Community surveys have confirmed the association
between IA and psoriasis. For example, a cross sectional
survey in primary care from North East England has
reported a prevalence of psoriasis of 1.7%, and of psoriasis
associated with IA of 0.3% [3]. Community surveys have
reported incidences of psoriasis in 4.5–5.3% of patients
presenting with IA [4,5], but the incidence may be even
higher for patients whom are seronegative for rheumatoid
factor [6]. Conversely, patients with psoriasis are more likely
to have IA [5]. This increased association supports the exis-
tence of a distinct disease, psoriatic arthritis (PsA).
Relationship between psoriasis and PsA
The evidence from these recent community-based
studies supports the association of IA and psoriasis, and
there are several explanations for how this increased
association occurs. One theory is that psoriasis and PsA
may be two completely separate diseases with different
susceptibility factors; the skin manifestation may simply
be the final common pathway. There is no difference in
type or distribution of psoriasis, however, between those
with or without arthritis. Another explanation is that psori-
asis and PsA may share susceptibility factors, which may
be genetic, environmental or both. Nearly all cases of
PsA develop in patients with psoriasis or a family history
of psoriasis, so it could be interpreted that psoriasis sus-
ceptibility factors are necessary for, but not sufficient to
cause, PsA. The development of PsA may require addi-
tional factors, either genetic or environmental. A third
explanation is that since synovial joint inflammation is
common to both RA and PsA, susceptibility factors may
be shared between these two conditions, but the pres-
ence of psoriasis may modify the expression in joints and
the pattern of joint involvement. It has been proposed,
however, that PsA is primarily a disease of enthesitis
with secondary synovial inflammation, and that arthritis
per se, in the presence of psoriasis, does not represent
PsA [7].
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Abstract
The existence of psoriatic arthritis as a distinct clinical entity remains a topic of debate; some authors
propose that it is simply the co-occurrence of psoriasis and inflammatory arthritis. However, a distinct
entity is likely to have distinct susceptibility factors in addition to those that contribute to psoriasis and
inflammatory arthritis alone. These aetiological factors may be genetic and/or environmental, and in this
review, the evidence for distinct psoriatic arthritis genetic susceptibility factors is considered.
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Whatever the mechanism of association, many clinicians
support the idea that a distinct clinical entity of PsA does
exist. Studies to prove the existence of PsA are limited,
however, by the lack of a good disease definition. PsA has
been broadly defined as “an inflammatory arthritis associ-
ated with psoriasis which is usually negative for rheuma-
toid factor” [1]. This definition has been widely criticised
and no internationally agreed criteria for the diagnosis of
PsA have ever been successfully developed and applied
(reviewed in [8]). Recently, classification criteria have
been proposed based on analysis of 260 PsA patients,
but these require validation [9]. Currently, however, most
clinicians make the diagnosis based on the presence of IA
in a patient with psoriasis after exclusion of other causes.
The controversy over the distinctiveness of PsA is important
to bear in mind when investigating potential susceptibility
factors. A distinct entity is likely to have a distinct aetiology
in addition to that of related inflammatory arthropathies that
may simply coincide with psoriasis [10,11]. These aetiologi-
cal factors may be genetic and/or environmental; this review
concentrates on the former. Demonstration of a genetic
association with PsA over and above the expected effects
of a combination of psoriasis and IA would support the
concept of PsA as a distinct disease.
Evidence for genetic susceptibility to PsA
Twin and family studies are the classic way of investigat-
ing genetic contribution to a disease but twin studies have
not, to my knowledge, yet been undertaken in PsA. Family
studies do, however, suggest that first-degree relatives are
at increased risk of developing PsA [1]. The sibling recur-
rence risk (λs) measures the excess risk to a sibling over
the general population risk and is estimated to be approxi-
mately four for psoriasis [12]. Moll and Wright’s original
family studies suggest that the λs for PsA may be signifi-
cantly higher, indicating an even stronger genetic contri-
bution to its aetiology [1].
Studies of linkage and association to the
human leukocyte-associated antigen region
Linkage to the human leukocyte-associated antigen C
gene (HLA C) has been reported consistently in psoriasis
sibling pair families, and association studies have revealed
that the HLA Cw*0602 allele is most commonly associ-
ated [13–20]. Recently the association has been refined
to a 100 kb telomeric region of the HLA C locus, sug-
gesting that the true susceptibility locus it is not HLA C,
but another gene in linkage disequilibrium (LD) with it [21].
Although several studies have reported a higher frequency
of  HLA Cw6 in PsA patients compared to controls
[22–33], only a few have compared allele frequencies
between PsA, psoriasis and controls [22,24,26,31].
These studies suggest that the primary association to the
gene is with psoriasis rather than PsA. Case control inves-
tigations of HLA have found that, although B13, DR7, and
B57 are all associated with PsA, the association may not
be independent of psoriasis and may be due to LD across
the region with Cw6 [22,24,25]. One study investigating
linkage in affected sibling pair families with psoriasis has
suggested that linkage to the HLA gene region is stronger
in those families without joint involvement, although no
attempt was made to make a diagnosis of PsA [18]. This
study raises the hypothesis, however, that HLA may not
contribute significant additional susceptibility to PsA over
psoriasis alone. Conversely, there have been reports of
association with PsA to the HLA B locus, particularly with
B7  and B27, independent of psoriasis [22,31,34]. The
association with B27 is particularly strong in PsA patients
with sacroiliitis, but it has also been detected in patients
with distal interphalangeal joint involvement, suggesting
that the HLA–B27 association may not simply reflect the
co-incidence of ankylosing spondylitis with psoriasis [31].
HLA–DR4 has been associated with a peripheral symmet-
rical arthritis suggesting an overlap with RA susceptibility
loci [24]. HLA B38 and B39 have both been associated
with PsA, and in one study the association of B38 was
independent of psoriasis [26], but neither of these is in LD
with Cw6 [23,24,26,28,30]. They may, however, be in LD
with a susceptibility gene mapping close by.
Non-HLA genes mapping to the MHC region
Other investigators have examined the possibility that a
non-HLA gene, mapping to the MHC region of chromo-
some 6p, may be a PsA susceptibility gene. MHC chain-
related gene A (MICA) is considered to be a candidate
gene because it is in LD with HLA B alleles and may, there-
fore, explain the association to these alleles. An association
of MICA to PsA has been reported to occur independently
of psoriasis [35] and a higher frequency of the trinucleotide
repeat MICA-A9 polymorphism in PsA patients compared
to controls has been replicated in a separate population
[36]. Even though the sample sizes in these studies were
small, this replication of findings suggests that the associa-
tion may be real. The tumour necrosis factor-α gene (TNF-
α) also maps close to the HLA B locus and is a strong
candidate gene because levels are known to be increased
in patients with psoriasis [37]. An association has been
found between haplotypes of microsatellite markers
mapping close to the TNF-α gene and PsA, independently
of psoriasis and independently of HLA Class I associa-
tions. An association with a promoter polymorphism (-308),
independent of the microsatellite haplotype association,
was also detected, leading the authors to speculate that
more than one susceptibility locus maps to the region [38].
The -238 TNF-α promoter polymorphism has previously
been associated with both juvenile-onset psoriasis and
PsA [39]. Two other studies, however, have failed to repli-
cate these findings. One was a Japanese study of 20 PsA
patients and 87 population controls [40] and the other
included 52 Jewish PsA patients and 73 controls [36].
Both studies were, therefore, considerably underpowered249
to exclude an association. No association between low
molecular protein (LMP) 2 or 7 polymorphisms [41] and
PsA has been detected, whilst the transporter associated
with antigen processing 1 (TAP1) *0101 allele has been
associated with psoriasis but not with PsA [42].
Non-HLA genes mapping outside the MHC
region
No evidence for association of T-cell receptor gene poly-
morphism and either psoriasis or PsA [25] has been
reported. Studies investigating association with the
immunoglobulin gene heavy chain have yielded conflicting
results: in a study of English patients an association was
found with PsA but not with psoriasis [43], but in Italian
patients the converse was reported [44]. The explanation
for the apparent contradiction is likely to relate to the small
numbers of patients investigated. This is a common
problem in most of the case control studies reported to
date. Small sample sizes result in low power to detect an
association and an increased chance of detecting spuri-
ous associations due to type I error. PsA is a particularly
difficult disease to study because the clinical manifesta-
tions are so heterogenous. Large sample sizes with suffi-
cient numbers to allow stratification of patients into more
homogenous subsets, whilst still retaining power to detect
an association, are required, but most studies to date have
been performed on small series of patients.
Future directions
Knowledge of other aspects of PsA pathogenesis may
help to identify candidate genetic susceptibility factors for
future investigation. For example, PsA, like psoriasis,
exhibits excessive paternal transmission, so evidence of
genomic imprinting exhibited by a putative susceptibility
gene would make it a stronger candidate [45].
Comparing RA to PsA, many of the differences observed
appear to be quantitative rather than qualitative. PsA syn-
ovium does, however, have increased vascularity and
fibrosis. E-selectin expression is also markedly reduced in
PsA and, while interleukin-2 is absent from RA synovium, it
is detectable in PsA synovium [46]. Genes encoding
these factors are, therefore, potential candidate PsA sus-
ceptibility genes.
Linkage to the long arm of chromosome 17 (17q25)
[13,18] and the short arm of chromosome 6 (6p) [13–19]
have been replicated in psoriasis-affected sibling pair fam-
ilies. Examination of genes mapping to these regions may
reveal evidence for a unique genetic contribution to PsA.
For example, the linkage to 17q25 has been found to be
stronger in psoriasis families with joint complaints (again,
no attempt was made to make a formal diagnosis of PsA
in these families) [18]. Recently, this region has been
linked to RA by two independent groups, which suggests
that a general arthritis susceptibility locus may map to the
region [47,48]. Linkage to the pericentric region of chro-
mosome 16 has been reported in Crohn’s disease [49],
psoriasis [20] and RA [48], again suggesting that a gener-
alised arthritis susceptibility locus may map to this region.
Recent work showing response of PsA patients to treat-
ment with soluble recombinant TNF receptor (TNFR)-2
fusion protein lends support for a role for this pathway in
PsA pathogenesis [50]. Although association to TNF-α
polymorphism has been demonstrated, polymorphism in
other genes involved in this pathway (e.g. TNFR1, TNFR2,
TNF cleavage enzyme gene [TACE]) may predispose
some groups of patients to susceptibility and are worthy of
investigation.
Conclusion
The investigation of PsA is challenging, not only because it
represents a ‘disease within a disease’ (PsA within psoria-
sis), but also because neither a disease definition nor clas-
sification criteria have yet been universally agreed upon.
Furthermore, there remains an ongoing debate regarding
the features that distinguish PsA from other inflammatory
arthropathies that may coincide with the presence of pso-
riasis. There is evidence for a strong genetic contribution
to PsA, which may be greater than that for RA or psoriasis
alone but few studies have attempted to identify genetic
susceptibility factors; those which have consistently
demonstrate an association between HLA and PsA, but it
is unclear whether the primary association is between
psoriasis and the major psoriasis susceptibility locus Cw6.
Association with 2 genes, MICA and the TNF-α locus
(which map within MHC but which are not classical HLA
genes) has now been replicated, independently of HLA
Class I associations. Studies of other candidate genes
have either not shown association or demonstrated asso-
ciation, which could not then be replicated. The majority of
studies have used a case control design, but sample sizes
have generally been small and the studies were under-
powered. Further research into this fascinating area is
required but, in attempting to study the genetics of PsA, it
is important to control carefully for psoriasis and its known
genetic factors. It is also important to study genes that are
potentially associated with other inflammatory
arthropathies, to determine whether unique PsA suscepti-
bility factors exist.
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